Precision Medicine in Interventional Cardiology: Implications for Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention

References

• Council NR . Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease.The National Academies Press, DC, USA,142 (2011).
   Google Scholar
• Incorvati JA , ShahS , MuY , LuJ. Targeted therapy for HER2 positive breast cancer. J. Hematol. Onco6, 38 (2013).
   PubMed Web of Science ®Google Scholar
• Duarte JD , CavallariLH. Pharmacogenetics to guide cardiovascular drug therapy. Nat. Rev. Cardiol.18(9), 649–665 (2021).
   PubMed Web of Science ®Google Scholar
• Galli M , FranchiF , RolliniF , AngiolilloDJ. Role of platelet function and genetic testing in patients undergoing percutaneous coronary intervention. Trends Cardiovasc. Med. S1050-1738(21) 00157-2 (2021).
   Web of Science ®Google Scholar
• Capodanno D , AlfonsoF , LevineGN , ValgimigliM , AngiolilloDJ. ACC/AHA versus ESC guidelines on dual antiplatelet therapy: JACC guideline comparison. J. Am. Coll. Cardiol.72(23 Pt A), 2915–2931 (2018).
   PubMed Web of Science ®Google Scholar
• Collet J-P , ThieleH , BarbatoEet al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J.42(14), 1289–1367 (2020).
   Web of Science ®Google Scholar
• Angiolillo DJ , GalliM , ColletJP , KastratiA , O’DonghueM. Antiplatelet therapy after percutaneous coronary intervention. Eurointervention. 17(17), e1371–e1396 (2022).
   PubMed Web of Science ®Google Scholar
• Valgimigli M , CostaF , LokhnyginaYet al. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. Eur. Heart J.38(11), 804–810 (2017).
   PubMed Web of Science ®Google Scholar
• Galli M , AndreottiF , D’AmarioDet al. Antithrombotic therapy in the early phase of non-ST-elevation acute coronary syndromes: a systematic review and meta-analysis. Eur. Heart J. Cardiovasc. Pharmacother.6(1), 43–56 (2020).
   PubMed Web of Science ®Google Scholar
• Aradi D , KirtaneA , BonelloLet al. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur. Heart J.36(27), 1762–1771 (2015).
   PubMed Web of Science ®Google Scholar
• Sibbing D , AradiD , AlexopoulosDet al. Updated expert consensus statement on platelet function and genetic testing for guiding P2Y(12) receptor inhibitor treatment in percutaneous coronary intervention. JACC Cardiovasc. Interv.12(16), 1521–1537 (2019).
   PubMed Web of Science ®Google Scholar
• Galli M , FranchiF , RolliniFet al. Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations. Expert Rev. Clin. Pharmacol.14(8), 963–978 (2021).
   PubMed Web of Science ®Google Scholar
• Galli M , BenenatiS , FranchiFet al. Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials. Eur. Heart J.43(10), 959–967 (2022).
   PubMed Web of Science ®Google Scholar
• Galli M , CapodannoD , AndreottiF , CreaF , AngiolilloDJ. Safety and efficacy of P2Y(12) inhibitor monotherapy in patients undergoing percutaneous coronary interventions. Expert Opin. Drug Saf.20(1), 9–21 (2021).
   PubMed Web of Science ®Google Scholar
• Ibanez B , JamesS , AgewallSet al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J.39(2), 119–177 (2018).
   PubMed Web of Science ®Google Scholar
• Neumann FJ , Sousa-UvaM , AhlssonAet al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur. Heart J.40(2), 87–165 (2019).
   PubMed Web of Science ®Google Scholar
• Scott SA , SangkuhlK , SteinCMet al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin. Pharmacol. Ther.94(3), 317–323 (2013).
   PubMed Web of Science ®Google Scholar
• Lee CR , LuzumJA , SangkuhlKet al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update. Clin. Pharmacol. Ther. doi:10.1002/cpt.2526 (2022) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Galli M , GargiuloG. Towards a personalized selection of antithrombotic agents in patients undergoing PCI: the role of clinical presentation in tools for risk assessment. J. Thromb. Thrombolysis53(2), 495–498 (2022).
   PubMed Web of Science ®Google Scholar
• Giustino G , ChieffoA , PalmeriniTet al. Efficacy and safety of dual antiplatelet therapy after complex PCI. J. Am. Coll. Cardiol.68(17), 1851–1864 (2016).
   PubMed Web of Science ®Google Scholar
• Capodanno D , BhattDL , GibsonCMet al. Bleeding avoidance strategies in percutaneous coronary intervention. Nat. Rev. Cardiol.19(2), 117–132 (2021).
   PubMed Web of Science ®Google Scholar
• Capodanno D , MoriceMC , AngiolilloDJet al. Trial design principles for patients at high bleeding risk undergoing PCI: JACC Scientific Expert Panel. J. Am. Coll. Cardiol.76(12), 1468–1483 (2020).
   PubMed Web of Science ®Google Scholar
• Bhatt DL , KaskiJC , DelaneySet al. Results of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous intervention. Int. J. Cardiol.337, 1–8 (2021).
   PubMed Web of Science ®Google Scholar
• Li-Wan-Po A , GirardT , FarndonP , CooleyC , LithgowJ. Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. Br. J. Clin. Pharmacol.69(3), 222–230 (2010).
   PubMed Web of Science ®Google Scholar
• Pereira NL , RihalCS , SoDYFet al. Clopidogrel pharmacogenetics. Circulation Cardiovascular Interventions12(4), e007811 (2019).
   PubMed Web of Science ®Google Scholar
• Moon JY , FranchiF , RolliniFet al. Role of genetic testing in patients undergoing percutaneous coronary intervention. Expert Rev. Clin. Pharmacol.11(2), 151–164 (2018).
   PubMed Web of Science ®Google Scholar
• Mega JL , CloseSL , WiviottSDet al. Cytochrome P-450 polymorphisms and response to clopidogrel. N. Engl. J. Med.360(4), 354–362 (2009).
   PubMed Web of Science ®Google Scholar
• Mega JL , SimonT , ColletJPet al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 304(16), 1821–1830 (2010).
   PubMed Web of Science ®Google Scholar
• Shuldiner AR , O’ConnellJR , BlidenKPet al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 302(8), 849–857 (2009).
   PubMed Web of Science ®Google Scholar
• Simon T , VerstuyftC , Mary-KrauseMet al. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med.360(4), 363–375 (2009).
   PubMed Web of Science ®Google Scholar
• Hochholzer W , TrenkD , FrommMFet al. Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J. Am. Coll. Cardiol.55(22), 2427–2434 (2010).
   PubMed Web of Science ®Google Scholar
• Lewis JP , StephensSH , HorensteinRBet al. The CYP2C19*17 variant is not independently associated with clopidogrel response. J. Thromb. Haemost.11(9), 1640–1646 (2013).
   PubMed Web of Science ®Google Scholar
• Lee CR , ThomasCD , BeitelsheesALet al. Impact of the CYP2C19*17 allele on outcomes in patients receiving genotype-guided antiplatelet therapy after percutaneous coronary intervention. Clin. Pharmacol. Ther.109(3), 705–715 (2021).
   PubMed Web of Science ®Google Scholar
• Wallentin L , JamesS , StoreyRFet al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 376(9749), 1320–1328 (2010).
   PubMed Web of Science ®Google Scholar
• Mega JL , CloseSL , WiviottSDet al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation. 119(19), 2553–2560 (2009).
   PubMed Web of Science ®Google Scholar
• Sugidachi A , OgawaT , KuriharaAet al. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel’s active metabolite. J. Thromb. Haemost.5(7), 1545–1551 (2007).
   PubMed Web of Science ®Google Scholar
• Trenk D , HochholzerW. Genetics of platelet inhibitor treatment. Br. J. Clin. Pharmacol.77(4), 642–653 (2014).
   PubMed Web of Science ®Google Scholar
• Capodanno D , DharmashankarK , AngiolilloDJ. Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist. Expert Rev. Cardiovasc. Ther.8(2), 151–158 (2010).
   PubMedGoogle Scholar
• Angiolillo DJ , UenoM , GotoS. Basic principles of platelet biology and clinical implications. Circulation J.74(4), 597–607 (2010).
   PubMed Web of Science ®Google Scholar
• Capodanno D , AngiolilloDJ. Antithrombotic therapy for atherosclerotic cardiovascular disease risk mitigation in patients with coronary artery disease and diabetes mellitus. Circulation142(22), 2172–2188 (2020).
   PubMed Web of Science ®Google Scholar
• Patti G , CavallariI , AndreottiFet al. Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs. Nat. Rev. Cardiol.16(2), 113–130 (2019).
   PubMed Web of Science ®Google Scholar
• Rollini F , FranchiF , Muñiz-LozanoA , AngiolilloDJ. Platelet function profiles in patients with diabetes mellitus. J. Cardiovasc. Transl. Res.6(3), 329–345 (2013).
   PubMed Web of Science ®Google Scholar
• Franchi F , RolliniF , AggarwalNet al. Pharmacodynamic comparison of prasugrel versus ticagrelor in patients with Type 2 diabetes mellitus and coronary artery disease: the OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 study. Circulation. 134(11), 780–792 (2016).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ , JakubowskiJA , FerreiroJLet al. Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with Type 2 diabetes and coronary artery disease. J. Am. Coll. Cardiol.64(10), 1005–1014 (2014).
   PubMed Web of Science ®Google Scholar
• Zhu HJ , WangX , GawronskiBE , BrindaBJ , AngiolilloDJ , MarkowitzJS. Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation. J. Pharmacol. Exp. Ther.344(3), 665–672 (2013).
   PubMed Web of Science ®Google Scholar
• Yao H , GuJ , ShanYet al. Type 2 diabetes mellitus decreases systemic exposure of clopidogrel active metabolite through upregulation of P-glycoprotein in rats. Biochem. Pharmacol.180, 114142 (2020).
   PubMed Web of Science ®Google Scholar
• Gravel S , ChiassonJL , TurgeonJ , GrangeonA , MichaudV. Modulation of CYP450 activities in patients with Type 2 diabetes. Clin. Pharmacol. Ther.106(6), 1280–1289 (2019).
   PubMed Web of Science ®Google Scholar
• Erlinge D , VarenhorstC , BraunOOet al. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. J. Am. Coll. Cardiol.52(24), 1968–1977 (2008).
   PubMed Web of Science ®Google Scholar
• Ferreiro JL , AngiolilloDJ. Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation. 123(7), 798–813 (2011).
   PubMed Web of Science ®Google Scholar
• Zhang R , MamzaJB , MorrisTet al. Lifetime risk of cardiovascular-renal disease in Type 2 diabetes: a population-based study in 473,399 individuals. BMC Medicine. 20(1), 63 (2022).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ , Fernandez-OrtizA , BernardoEet al. Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes. 55(3), 780–784 (2006).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ , BernardoE , SabatéMet al. Impact of platelet reactivity on cardiovascular outcomes in patients with Type 2 diabetes mellitus and coronary artery disease. J. Am. Coll. Cardiol.50(16), 1541–1547 (2007).
   PubMed Web of Science ®Google Scholar
• Franchi F , JamesSK , LakicTGet al. Impact of diabetes mellitus and chronic kidney disease on cardiovascular outcomes and platelet P2Y(12) receptor antagonist effects in patients with acute coronary syndromes: insights from the PLATO trial. J. Am. Heart Association8(6), e011139 (2019).
   PubMed Web of Science ®Google Scholar
• Wiviott SD , BraunwaldE , AngiolilloDJet al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel – Thrombolysis in Myocardial Infarction 38. Circulation. 118(16), 1626–1636 (2008).
   PubMed Web of Science ®Google Scholar
• Steg PG , BhattDL , SimonTet al. Ticagrelor in patients with stable coronary disease and diabetes. N. Engl. J. Med.381(14), 1309–1320 (2019).
   PubMed Web of Science ®Google Scholar
• Bhatt DL , BonacaMP , BansilalSet al. Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS-TIMI 54. J. Am. Coll. Cardiol.67(23), 2732–2740 (2016).
   PubMed Web of Science ®Google Scholar
• Nardin M , VerdoiaM , SartoriCet al. Body mass index and platelet reactivity during dual antiplatelet therapy with clopidogrel or ticagrelor. J. Cardiovasc. Pharmacol.66(4), 364–370 (2015).
   PubMed Web of Science ®Google Scholar
• Baber U , MehranR , KirtaneAJet al. Prevalence and impact of high platelet reactivity in chronic kidney disease: results from the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents registry. Circ. Cardiovasc. Interv.8(6), e001683 (2015).
   PubMed Web of Science ®Google Scholar
• Park DW , AhnJM , SongHGet al. Differential prognostic impact of high on-treatment platelet reactivity among patients with acute coronary syndromes versus stable coronary artery disease undergoing percutaneous coronary intervention. Am. Heart J.165(1), 34–42.e1 (2013).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ , CapodannoD , DanchinNet al. Derivation, validation, and prognostic utility of a prediction rule for nonresponse to clopidogrel: the ABCD-GENE score. JACC Cardiovas. Interv.13(5), 606–617 (2020).
   PubMed Web of Science ®Google Scholar
• Capodanno D , AngiolilloDJ , LennonRJet al. ABCD-GENE score and clinical outcomes following percutaneous coronary intervention: insights from the TAILOR-PCI trial. J. Am. Heart Association11(4), e024156 (2022).
   PubMed Web of Science ®Google Scholar
• Dai L , XuJ , YanHet al. Application of age, body mass index, chronic kidney disease, diabetes, and genotyping score for efficacy of clopidogrel: secondary analysis of the CHANCE trial. Stroke. 53(2), 465–472 (2022).
   PubMed Web of Science ®Google Scholar
• Man M , FarmenM , DumaualCet al. Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans. J. Clin. Pharmacol.50(8), 929–940 (2010).
   PubMed Web of Science ®Google Scholar
• Alrajeh KY , RomanYM. The frequency of major CYP2C19 genetic polymorphisms in women of Asian, Native Hawaiian and Pacific Islander subgroups. Personalized Med.19(4), 327–339 (2022).
   PubMedGoogle Scholar
• Kwon O , ParkD-W. Antithrombotic therapy after acute coronary syndromes or percutaneous coronary interventions in East Asian populations. JACC. 2(1), 1–18 (2022).
   PubMedGoogle Scholar
• Kim HK , TantryUS , SmithSCJret al. The East Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease. Thromb. Haemost.121(4), 422–432 (2021).
   PubMedGoogle Scholar
• Levine GN , JeongYH , GotoSet al. Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nat. Rev. Cardiol.11(10), 597–606 (2014).
   PubMed Web of Science ®Google Scholar
• Valgimigli M , GragnanoF , BrancaMet al. P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials. BMJ (Clin. Res. Ed.)373, n1332 (2021).
   PubMed Web of Science ®Google Scholar
• Gustafson C , GowerMN , WilliamsAKet al. Effect of gender on clinical outcomes in patients receiving CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention. Circulation. 13(5), 554–556 (2020).
   PubMed Web of Science ®Google Scholar
• Franchi F , RolliniF , ChoJR , FerranteE , AngiolilloDJ. Platelet function testing in contemporary clinical and interventional practice. Curr. Treat. Options Cardiovasc. Med.16(5), 300 (2014).
   PubMedGoogle Scholar
• Angiolillo DJ . Dual antiplatelet therapy guided by platelet function testing. Lancet. 390(10104), 1718–1720 (2017).
   PubMed Web of Science ®Google Scholar
• Galli M , FranchiF. Guided selection of antiplatelet therapy in acute coronary syndrome: impact on outcomes and resources utilization. Int. J. Cardiol.345, 36–38 (2021).
   PubMed Web of Science ®Google Scholar
• Claassens DMF , VosGJA , BergmeijerTOet al. A genotype-guided strategy for oral P2Y(12) inhibitors in primary PCI. N. Engl. J. Med.381(17), 1621–1631 (2019).
   PubMed Web of Science ®Google Scholar
• Sibbing D , AradiD , JacobshagenCet al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet. 390(10104), 1747–1757 (2017).
   PubMed Web of Science ®Google Scholar
• Galli M , BenenatiS , CapodannoDet al. Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Lancet. 397(10283), 1470–1483 (2021).
   PubMed Web of Science ®Google Scholar
• Cadroy Y , BossavyJP , ThalamasC , SagnardL , SakariassenK , BoneuB. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation. 101(24), 2823–2828 (2000).
   PubMed Web of Science ®Google Scholar
• Hindricks G , PotparaT , DagresNet al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur. Heart J.42(5), 373–498 (2020).
   Web of Science ®Google Scholar
• Gibson CM , MehranR , BodeCet al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N. Engl. J. Med.375(25), 2423–2434 (2016).
   PubMed Web of Science ®Google Scholar
• Cannon CP , BhattDL , OldgrenJet al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N. Engl. J. Med.377(16), 1513–1524 (2017).
   PubMed Web of Science ®Google Scholar
• Lopes RD , HeizerG , AronsonRet al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N. Engl. J. Med.380(16), 1509–1524 (2019).
   PubMed Web of Science ®Google Scholar
• Vranckx P , ValgimigliM , EckardtLet al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 394(10206), 1335–1343 (2019).
   PubMed Web of Science ®Google Scholar
• Galli M , AndreottiF , D’AmarioDet al. Randomised trials and meta-analyses of double vs triple antithrombotic therapy for atrial fibrillation-ACS/PCI: a critical appraisal. Int. J. Cardiol. Heart Vasculature28, 100524 (2020).
   PubMed Web of Science ®Google Scholar
• Capodanno D , DiMaio M , GrecoAet al. Safety and efficacy of double antithrombotic therapy with non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation undergoing percutaneous coronary intervention: a systematic review and meta-analysis. J. Am. Heart Association9(16), e017212 (2020).
   PubMed Web of Science ®Google Scholar
• Gargiulo G , GoetteA , TijssenJet al. Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. Eur. Heart J.40(46), 3757–3767 (2019).
   PubMed Web of Science ®Google Scholar
• Galli M , AndreottiF , D’AmarioDet al. Dual therapy with direct oral anticoagulants significantly increases the risk of stent thrombosis compared to triple therapy. Eur. Heart J. Cardiovasc. Pharmacother.6(2), 128–129 (2020).
   PubMed Web of Science ®Google Scholar
• Galli M , AndreottiF , PortoI , CreaF. Intracranial haemorrhages vs. stent thromboses with direct oral anticoagulant plus single antiplatelet agent or triple antithrombotic therapy: a meta-analysis of randomized trials in atrial fibrillation and percutaneous coronary intervention/acute coronary syndrome patients. Europace. 22(4), 538–546 (2020).
   PubMed Web of Science ®Google Scholar
• Galli M , AndreottiF , D’AmarioD , PortoI , CreaF. Stent thrombosis with dual antithrombotic therapy in atrial fibrillation-ACS/PCI trials. J. Am. Coll. Cardiol.75(14), 1727–1728 (2020).
   PubMed Web of Science ®Google Scholar
• Schömig A , NeumannFJ , KastratiAet al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N. Engl. J. Med.334(17), 1084–1089 (1996).
   PubMed Web of Science ®Google Scholar
• Leon MB , BaimDS , PopmaJJet al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent anticoagulation restenosis study investigators. N. Engl. J. Med.339(23), 1665–1671 (1998).
   PubMed Web of Science ®Google Scholar
• O’Donoghue ML , MurphySA , SabatineMS. The safety and efficacy of aspirin discontinuation on a background of a P2Y(12) inhibitor in patients after percutaneous coronary intervention: a systematic review and meta-analysis. Circulation. 142(6), 538–545 (2020).
   PubMed Web of Science ®Google Scholar
• Benenati S , GalliM , DeMarzo Vet al. Very short vs. long dual antiplatelet therapy after second generation drug-eluting stents in 35 785 patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials. Eur. Heart J. Cardiovasc. Pharmacother.7(2), 86–93 (2021).
   PubMed Web of Science ®Google Scholar
• Watanabe H , MorimotoT , NatsuakiMet al. Comparison of clopidogrel monotherapy after 1 to 2months of dual antiplatelet therapy with 12months of dual antiplatelet therapy in patients with acute coronary syndrome: the STOPDAPT-2 ACS randomized clinical trial. JAMA Cardiology. 7(4), 407–417 (2022).
   PubMed Web of Science ®Google Scholar
• De Luca L , D’AscenzoF , MusumeciGet al. Incidence and outcome of switching of oral platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: the SCOPE registry. Eurointervention. 13(4), 459–466 (2017).
   PubMed Web of Science ®Google Scholar
• Franchi F , RolliniF , RivasRios Jet al. Pharmacodynamic effects of switching from ticagrelor to clopidogrel in patients with coronary artery disease: results of the SWAP-4 study. Circulation. 137(23), 2450–2462 (2018).
   PubMed Web of Science ®Google Scholar
• Cuisset T , DeharoP , QuiliciJet al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (Timing of Platelet Inhibition after acute coronary syndrome) randomized study. Eur. Heart J.38(41), 3070–3078 (2017).
   PubMed Web of Science ®Google Scholar
• Kim H-S , KangJ , HwangDet al. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial. Lancet. 396(10257), 1079–1089 (2020).
   PubMed Web of Science ®Google Scholar
• Kim CJ , ParkMW , KimMCet al. Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial. Lancet. 398(10308), 1305–1316 (2021).
   PubMed Web of Science ®Google Scholar